Status:
COMPLETED
Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsors:
Makerere University
Conditions:
HIV Infections
Tuberculosis
Eligibility:
All Genders
13-60 years
Phase:
PHASE3
Brief Summary
This study is designed to determine whether 6 months of anti-HIV drugs given along with tuberculosis treatment will delay the onset of AIDS in HIV infected African patients.
Detailed Description
Tuberculosis (TB) is a common and serious complication of HIV infection in the developing world, especially in sub-Saharan Africa. Since the emergence of the HIV epidemic in Africa, the incidence rate...
Eligibility Criteria
Inclusion
- Diagnosis of pulmonary TB (AFB smear-positive or culture-positive)
- HIV infected
- CD4 count greater than 350 cells/mm3
- Residence within 20 km of Kampala, Uganda
- Willing to use acceptable forms of contraception during the study and for 6 weeks after stopping study medication
- Parent or guardian willing to provide informed consent, if applicable
Exclusion
- Pregnancy
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT00078247
Start Date
October 1 2004
Last Update
August 12 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Makerere University Medical School
Kampala, Uganda